Effectiveness of Spironolactone Plus Ambrisentan for Treatment of Pulmonary Arterial Hypertension (from the [ARIES] Study 1 and 2 Trials)

In translational models of pulmonary arterial hypertension (PAH), spironolactone improves cardiopulmonary hemodynamics by attenuating the adverse effects of hyperaldosteronism on endothelin type-B receptor function in pulmonary endothelial cells. This observation suggests that coupling spironolacton...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Maron, Bradley A., Waxman, Aaron B., Opotowsky, Alexander R., Gillies, Hunter, Blair, Christiana, Aghamohammadzadeh, Reza, Loscalzo, Joseph, Leopold, Jane A.
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3906683/
https://ncbi.nlm.nih.gov/pubmed/23751938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.amjcard.2013.04.051
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares